Japan · Delayed Price · Currency is JPY Nippon Shinyaku Company Description
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally.
The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements.
The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II.
Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
| Country | Japan |
| Founded | 1911 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,309 |
| CEO | Toru Nakai |
Contact Details
Address: 14, Nishinosho-Monguchi-cho Kyoto, 601-8550 Japan | |
| Phone | 81 7 5321 1111 |
| Website | nippon-shinyaku.co.jp |
Stock Details
| Ticker Symbol | 4516 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3717600005 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Toru Nakai | Chief Executive Officer |
| Hideyuki Fujii | Chief Financial Officer |